Table 1.
Patient demographics and clinical characteristics
| Primary cohort (419) | Validation cohort (150) | P value | |
|---|---|---|---|
| Characteristic | No. (%) | No. (%) | |
| Age(Median) | |||
| <57 | 203(48.45%) | 70(46.67%) | 0.708 |
| ≥57 | 216(51.55%) | 80(53.33%) | |
| Sex | |||
| Male | 374(89.26%) | 135(90.00%) | 0.800 |
| Female | 45(10.74%) | 15(10.00%) | |
| OS status | |||
| Survive | 314(74.94%) | 131(87.33%) | 0.002 |
| Dead | 105(25.06%) | 19(12.67%) | |
| DFS status | |||
| Survive | 310(73.99%) | 129(86.00%) | 0.003 |
| Dead/ recurrence | 109(26.01%) | 21(14%) | |
| BMI | |||
| <18.5 | 39(9.31%) | 14(3.34%) | 0.996 |
| 18.5-25 | 280(66.83%) | 98(23.39%) | |
| ≥25 | 90(21.48%) | 32(7.64%) | |
| Family history | |||
| No | 329(78.52%) | 119(79.33%) | 0.872 |
| Yes | 89(21.24%) | 31(20.67%) | |
| Alcohol | |||
| No | 270(64.43%) | 102(68.00%) | 0.432 |
| Yes | 149(35.56%) | 48(32.00%) | |
| ECOG | |||
| 0-1 | 412(98.33%) | 144(96.00%) | 0.101 |
| 2 | 7(1.67%) | 6(4.00%) | |
| Clinical stage | |||
| Ⅰ | 213(50.84%) | 81(54.00%) | 0.584 |
| Ⅱ | 86(20.53%) | 25(16.67%) | |
| Ⅲ-Ⅳ | 120(28.64%) | 44(29.33%) | |
| Tumor stage | |||
| T1 | 216(51.55%) | 82(54.67%) | 0.522 |
| T2 | 94(22.43%) | 27(18.00%) | |
| T3-T4 | 109(26.01%) | 41(27.33%) | |
| Node stage | |||
| N0 | 396(94.51%) | 139(92.67%) | 0.414 |
| N1 | 23(5.49%) | 11(7.33%) | |
| Metastasis stage | |||
| M0 | 401(95.70%) | 143 (95.33%) | 0.147 |
| M1 | 18(4.30%) | 7(4.67%) | |
| HBs Ag | |||
| Negative | 69(16.47%) | 31(20.67%) | 0.329 |
| Positive | 335(79.95%) | 119(79.33%) | |
| AST(U/L) | |||
| <40 | 232(55.37%) | 84(56.00%) | 0.894 |
| ≥40 | 187(44.63%) | 66(44.00%) | |
| ALT(U/L) | |||
| <50 | 270(64.44%) | 104(69.33%) | 0.278 |
| ≥50 | 149(35.56%) | 46(30.67%) | |
| LDH(U/L) | |||
| <250 | 343(81.86%) | 122(81.33%) | 0.886 |
| ≥250 | 76(18.14%) | 28(18.67%) | |
| GGT(U/L) | |||
| <60 | 216(51.55%) | 76(50.67%) | 0.852 |
| ≥60 | 203(48.45%) | 74(49.33%) | |
| ALB(g/L) | |||
| <28 | 6(1.43%) | 1(0.67%) | 0.743 |
| 28-35 | 28(6.68%) | 11(7.33%) | |
| ≥35 | 385(91.89%) | 138(92.00%) | |
| TBIL(umol/L) | |||
| <34.2 | 406(96.90%) | 150(100.00%) | 0.092 |
| 34.2-51.3 | 6(1.43%) | 0(0.00%) | |
| ≥51.3 | 7(1.67%) | 0(0.00%) | |
| PT(sec) | |||
| <13.5 | 366(87.35%) | 136(90.67%) | 0.222 |
| ≥13.5 | 52(12.41%) | 13(8.67%) | |
| CEA(ng/ml) | |||
| <5 | 358(85.44%) | 125(83.33%) | 0.496 |
| ≥5 | 60(14.31%) | 25(16.67%) | |
| CA199(U/ml) | |||
| <35 | 278(66.35%) | 97(64.67%) | 0.942 |
| ≥35 | 127(30.31%) | 45(30.00%) |